eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
This is a test
Share book
- 392 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
Book details
Book preview
Table of contents
Citations
About This Book
This "patient-oriented" book was written as a meeting ground for practicing clinicians, allied health professionals, and clinical researchers to provide a practical guide for the contemporary assessment and management of patients with heart failure and cardiomyopathy. It revolves around broad patient scenarios to elegantly (or expertly) guide diagnostic and management strategies. Combining the talents of over one-hundred experts in the field, the book also endeavors to challenge the reader with areas of current controversies and opportunities for clinical investigation with the goals of both orienting clinicians and stimulating their research passions.
Key Features
-
- Provides practical guidance based on real-life heart failure scenarios
-
- Discusses both acute and chronic care patient-oriented scenarios
-
- Covers up-to-date and novel concepts in heart failure
-
- Features the perspectives of current debates and controversies in heart failure
-
- Highlights the opportunities for research in this field
Frequently asked questions
How do I cancel my subscription?
Can/how do I download books?
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
What is the difference between the pricing plans?
Both plans give you full access to the library and all of Perlegoās features. The only differences are the price and subscription period: With the annual plan youāll save around 30% compared to 12 months on the monthly plan.
What is Perlego?
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, weāve got you covered! Learn more here.
Do you support text-to-speech?
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Is Heart Failure an online PDF/ePUB?
Yes, you can access Heart Failure by Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler in PDF and/or ePUB format, as well as other popular books in Medicine & Medical Theory, Practice & Reference. We have over one million books available in our catalogue for you to explore.
Information
Section III
Managing Chronic Heart Failure
DOI: 10.1201/9780429244544-12
Chapter 10 Outpatient Management of Stable Heart Failure with Reduced Ejection Fraction
Chapter 11 Exercise and Rehabilitation in Heart Failure
Chapter 12 The Patient with Ischemic Heart Failure
Chapter 13 The Non-Ischemic HEART FAILURE Patient
Chapter 14 Valvular Heart Disease and Heart Failure
Chapter 15 The Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
Chapter 16 Heart Failure with Recovered Ejection Fraction (HFrecEF) and Heart Failure with Midrange Ejection Fraction (HFmrEF)
Chapter 17 The Advanced HEART FAILURE Patient
Chapter 18 Palliative Care and Advanced Directives in Heart Failure
Chapter 10
OUTPATIENT MANAGEMENT OF STABLE HEART FAILURE WITH REDUCED EJECTION FRACTION
Leah Reid, Jonathan Murrow, Kent Nilsson, and Catherine Marti
DOI: 10.1201/9780429244544-13
Introduction
Although therapies for HF with preserved ejection fraction (HFpEF) are lacking, there are many therapies available to patients with HF with reduced ejection fraction (HFrEF), regardless of symptomatology.1 Careful consideration should be taken at every encounter to evaluate not only volume status but also to optimize guideline-directed medical therapy as well as device therapy. In this chapter, we outline the current therapy available for outpatient management of HFrEF (Table 10.1).
| Starting Dose (mg) | Target Dose (mg) |
Beta-Blockers | ||
Bisoprolol | 1.25 daily | 10 daily |
Carvedilol | 3.125 b.i.d. | 25 b.i.d. for weight <85 kg and 50 b.i.d. for weight ā„85 kg |
Metoprolol succinate | 12.5ā25 daily | 200 daily |
Angiotensin Receptor Neprilysin Inhibitors | ||
Sacubitril/valsartan | 24/26ā49/51 b.i.d. | 97/103 b.i.d. |
Angiotensin-Converting Enzyme Inhibitors | ||
Captopril | 6.25 t.i.d. | 50 t.i.d. |
Enalapril | 2.5 b.i.d. | 10ā20 b.i.d. |
Lisinopril | 2.5ā5.0 daily | 20ā40 daily |
Ramipril | 1.25 daily | 10 daily |
Angiotensin II Receptor Blockers | ||
Candesartan | 4ā8 daily | 32 daily |
Losartan | 25ā50 daily | 150 daily |
Valsartan | 40 b.i.d. | 160 b.i.d. |
Aldosterone Antagonists | ||
Eplerenone | 25 daily | 50 daily |
Spironolactone | 12.5ā25 daily | 25ā50 daily |
Sodium-Glucose Cotransporter-2 Inhibitors | ||
Dapagliflozin | 10 daily | 10 daily |
Empagliflozin | 10 daily | 10 daily |
Vasodilators | ||
Hydralazine | 25 t.i.d. | 75 t.i.d. |
Isosorbide dinitrate | 20 t.i.d. | 40 t.i.d. |
Fixed-dose combination isosorbide dinitrate/hydralazine | 20/37.5 (1 tab) t.i.d. | 2 tabs t.i.d. |
Ivabradine | ||
Ivabradine | 2.5ā5 b.i.d. | Titrate to heart rate 50ā60 beats/min. Maximum dose 7.5 b.i.d. |
Notes: Isosorbide mononitrate is not recommended by current guidelines, which consider either the fixed-dose combination or the separate combination of isosorbide dinitrate and hydralazine as appropriate guideline-directed therapies for heart failure. | ||
Abbreviations: b.i.d. = bis in die (twice daily); t.i.d. = ter in die (three times daily). | ||
Source: Reproduced with permission from: Maddox et al., J Am Coll Cardiol 2021;77:772ā810. |
Beta-Blockers
Maladaptive activation of the sympathetic nervous system in HFrEF can lead to worsening congestion, malperfusion, and arrhythmias.2 Blockade of Ī²-adrenergic receptors has proven in multiple clinical trials to reduce morbidity and mortalityāspecifically with metoprolol succinate and bisoprolol, which selectively block Ī²-1-receptors, and with carvedilol, which selectively blocks Ī±-1, Ī²-1 and Ī²-2 receptors.3
In the landmark Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), patients with HFrEF (ejection fraction [EF] ā¤35%) and New York Heart Association (NYHA) class IIāIV symptoms had a 34% relative risk reduction in all-cause mortality with bisoprolol therapy vs placebo.4 The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) and carvedilol trials likewise demonstrated reduced risk of death or HF hospitalization (Figure 10.1).5ā7 To reduce morbidity and mortality, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Heart Failure Guidelines thus recommend using either bisoprolol, carvedilol, or sustained-release metoprolol succinate for all patients with current or prior symptoms of HFrEF unless contraindicated (class I, level of evidence [LOE]: A). Importantly, the benefit of Ī² blockers is dose dependent, with lower achieved heart rates associated with improved outcomes, albeit this effect is mostly relevant to patients in sinus rhythm and not among those with atrial fibrillation.8 A network meta-analysis of 21 trials found a mortality benefit of Ī² blockers vs p...